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Mechanisms and pathways of growth
failure in primordial dwarfism
Anna Klingseisen and Andrew P. Jackson1
MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU,
United Kingdom
The greatest difference between species is size; however,
the developmental mechanisms determining organism
growth remain poorly understood. Primordial dwarf-
ism is a group of human single-gene disorders with
extreme global growth failure (which includes Seckel
syndrome, microcephalic osteodysplastic primordial
dwarfism I [MOPD] types I and II, and Meier-Gorlin
syndrome). Ten genes have now been identified for mi-
crocephalic primordial dwarfism, encoding proteins in-
volved in fundamental cellular processes including
genome replication (ORC1 [origin recognition complex
1], ORC4, ORC6, CDT1, and CDC6), DNA damage
response (ATR [ataxia-telangiectasia and Rad3-related]),
mRNA splicing (U4atac), and centrosome function
(CEP152, PCNT, and CPAP). Here, we review the cellular
and developmental mechanisms underlying the patho-
genesis of these conditions and address whether further
study of these genes could provide novel insight into the
physiological regulation of organism growth.
Growth is an important developmental problem
From the smallest (bumble bee bat, 2 g) to the largest (blue
whale, 150,000 kg), there is a 75-million-fold difference in
the extremes of mammalian growth (Oldham et al. 2000).
Likewise, there is substantial variation in the relative size
of individual organs. Notably, the brain has undergone
a specific and dramatic expansion during evolution to
humans, with a 1000-fold increase in cortical surface area
occurring between mice and humans (Rakic 1995). How-
ever, our knowledge of factors determining organ and
organism size remains limited, in contrast to the extensive
knowledge of developmental signaling pathways that
determine body pattern. We do not know why humans
grow to be larger than mice (Conlon and Raff 1999) or
how our arms grow to be the same length (Wolpert 2010).
Likewise, we do not know what evolutionary changes
caused our brains to expand. Growth dysregulation un-
derlies much human disease and is an essential feature
of carcinogenesis.
The overall aim of this review is to place the primordial
dwarfism genes in the context of current developmental and
cellular knowledge of growth and to explore the mecha-
nisms by which gene mutations perturb growth. We there-
fore start by providing a brief overview of organism growth
and key regulatory pathways in order to provide context.
However, this is necessarily selective, and for a more sub-
stantive overview the reader is directed to the excellent
reviews on the biology of growth regulation written over
recent years (e.g., Conlon and Raff 1999; Leevers and
McNeill 2005; Edgar 2006; Cook and Tyers 2007).
What determines organism size?
The size of organisms is set the moment embryogenesis
begins. With little variation, flies, mice, humans, and
whales attain reproducible sizes. Similarly, organs grow to
sizes appropriate to the dimensions of the whole organism.
Precisely how genetic programs set such growth limits
remains to be elucidated.
Overall size is effectively determined by the composite
of cell number and cell volume (Conlon and Raff 1999).
Variance in either factor can determine organism size
(Fig. 1). In Caenorhabditis elegans, organism size can be
changed by up to a factor of 10 through variation in cell
volume alone (Watanabe et al. 2007). However, in other
species, altered cell size has no net effect on body size, as
classically demonstrated in the case of the salamander,
where tetraploid animals have cells twice as large as
diploid animals but remain the same size, having half the
number of cells (Fankhauser 1939).
In mammals, size differences appear to be determined
by cell number: The 3000-fold difference in body mass
between humans and mice (Fig. 1B) is accounted for by an
;3000-fold change in cell number (Conlon and Raff 1999).
Total cell number is the summation of cells accumulated
by cellular proliferation less those lost through cell death.
Developmental regulation must inevitably act on one of
these two processes. Experimentally, this is exemplified
by the dramatic effect on embryonic mouse brain size of
altered neural progenitor proliferation (Fig. 1C) or by
inhibition of apoptosis (Kuida et al. 1998; Roth et al.
2000; Chenn and Walsh 2002).
[Keywords: DNA damage response; DNA replication; cell cycle; centro-
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Although on one level mammalian body size can be
reduced to the simple problem of controlling cell num-
bers output during development, the determination of
body size is in fact the complex integration of many
factors. At the cellular level, cellular proliferation evi-
dently controls cell number, regulated intrinsically by
cell cycle regulators and extrinsically by mitogens. Like-
wise, cell differentiation (resulting in cells exiting from
cell cycle) and programmed cell death impact on cell
number. Less obviously, cell mass is also an important
determinant of cell proliferation, itself regulated by in-
trinsic factors as well as extrinsically by growth factors
and nutrition. Simply to maintain size, cells must double
in mass before each cell division. In yeast, it is well
established that there is a ‘‘restriction point’’ where cells
halt progress in G1 or G2 if they have not grown to
a minimum size (Hartwell et al. 1974; Nurse 1975;
Jorgensen and Tyers 2004). In metazoans, the situation is
less clear, with different experimental systems providing
conflicting evidence on the existence of an equivalent ‘‘cell
size checkpoint’’ (Echave et al. 2007; Tzur et al. 2009). At
the tissue/organ level, further regulation is present, with
organs growing to set sizes (the ‘‘organ checkpoint’’)
(Leevers and McNeill 2005), and growth regulation of the
whole organism is also controlled by the growth hormone/
insulin-like growth factor 1 (GH/IGF1) endocrine axis
(Netchine et al. 2011). Additional regulative complexity
is provided by opposing signals that stimulate growth and
cell survival and those restricting cell size and number
(Lui and Baron 2011). Furthermore, regulation of tissue
morphogenesis and growth are tightly intertwined, with
many morphogens having potent growth-stimulating
properties (Leevers and McNeill 2005; Crickmore and
Mann 2008).
Cellular pathways regulating growth
Organism development requires high-fidelity regulatory
networks to control and coordinate patterning and growth.
Important signaling pathways influencing organ and or-
ganism size are summarized in Figure 2. These include
insulin growth factor signaling, the Hippo signaling cas-
cade, and the mitogen-activated protein kinase (MAPK)
pathways. Also, morphogens such as TGF-b, Notch, and
Wnt are potent regulators of growth alongside their key
roles in patterning.
A common theme for these pathways is their integra-
tion of multiple inputs and subsequent action on a range
of overlapping downstream effectors that modulate
growth through cell mass, cell survival, and/or cellular
proliferation. The detailed study of growth mutants in
model organisms has contributed to the definition of the
pathways. Likewise, mutations in some components also
cause human genetic syndromes, which exhibit altered
growth. In contrast, rather than acting in these signal-
ing pathways, primordial dwarfism genes encode down-
stream cell proliferation/cell survival proteins. Here, we
briefly outline the nature of these pathways, with par-
ticular emphasis on downstream effectors to provide
a framework for a later examination of how primordial
dwarfism genes relate to them (see ‘‘Are primordial
dwarfism genes regulators of physiological growth?’’).
IGF signaling/target of rapamycin (TOR) pathway:
growth regulation through biosynthesis
and cell growth
Growth hormones play an important part in defining
adult body size through systemic hormonal regulation of
growth, with mutations in components of the GH/IGF1
axis causing a substantial reduction in human height
(Savage et al. 2010). Downstream from the IGF1 receptor,
this pathway integrates with other growth signals through
the TOR kinase. This kinase integrates IGF1, growth
factor, nutrient, and cellular energy signals via an exten-
sive signaling network (Fig. 3A; Caron et al. 2010).
Downstream, this master regulator of growth then mod-
ulates ribosome biogenesis and translation initiation
(Wullschleger et al. 2006). It promotes protein synthesis
through the phosphorylation and activation of transla-
tional machinery components (Guertin and Sabatini 2007)
and inhibits protein degradation (Wullschleger et al. 2006)
to promote growth in cell mass.
The insulin/TOR signaling pathway therefore inte-
grates endocrine (GH/IGF) and paracrine (growth factors)
Figure 1. (A) Cell size and cell number determine organism
size. Conceptually, body size can be altered through reducing
the number of cell divisions or reducing cell size. For example, if
during an identical period of development, cells divide only five
times out of the usual seven rounds of cell division, this will
reduce body volume by 75%. Reducing cell volume to a quarter
of normal could similarly reduce body size while maintaining
cell number constant. (B) In mammals, body size appears to be
predominantly determined by cell number. There is a 3000-fold
difference in body mass between mice (25 g) and humans (70 kg),
while volume of cells from similar tissues remains relatively
unchanged (Conlon and Raff 1999). (C) Cell number can be
increased in mammals through alterations in proliferation
kinetics. For instance, transgenic expression of stabilized b-cat-
enin protein enlarges brain size in mice during embryogenesis.
Midcoronal sections through the embryonic day 15.5 (E15.5)
cerebral cortex from a control mouse embryo (left) and a mouse
with the D90b-catenin-GFP transgene expressed in neural pre-
cursors, resulting in an enlarged brain with increased cerebral
cortical surface area and folds resembling sulci and gyri of
higher mammals. Bar, 1 mm. (Image from Chenn and Walsh
2002. Reprinted with permission from AAAS.)
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signals with nutritional status and available energy levels
to promote organism growth through increasing cell size
(Hietakangas and Cohen 2009). In contrast, the more
recently discovered Hippo signaling pathway acts to re-
strict organ growth, inhibiting cell cycle progression as
well as promoting apoptosis (Pan 2010).
The Hippo signaling pathway: controlling organ growth
by regulation of proliferation and cell death
The Hippo serine/threonine kinase is a key component of
a growth regulatory pathway conserved from Drosophila
to mammals (Dong et al. 2007). In Drosophila, upstream
components include atypical cadherins (Bennett and
Harvey 2006; Dong et al. 2007) and apical–basal polarity
proteins (Grusche et al. 2010), implicating cell adhesion
and cell polarity as important inputs to this pathway (Fig.
3B). Downstream, the pathway converges to repress the
activity of the transcriptional coactivator Yorkie (Yki)
through its phosphorylation and consequent exclusion
from the nucleus (Dong et al. 2007). Yki binds multiple
transcriptional targets to promote cell proliferation and
cell survival. In Drosophila, these include the cell cycle
regulators E2F1 (Goulev et al. 2008) and Cyclin E (Tapon
et al. 2002), the growth-promoting microRNA bantam
(Thompson and Cohen 2006), and the anti-apoptotic
protein dIAP (Drosophila inhibitor of apoptosis) (Tapon
et al. 2002). Furthermore, the transcription factor dMyc is
also a Yki target, which through its own wide range of
target genes drives cell proliferation (Neto-Silva et al.
2010; Ziosi et al. 2010).
Overall, the physiological functions for Hippo signal-
ing appear to be in ensuring timely transition from cell
proliferation to cellular quiescence and in ensuring proper
cellular differentiation (Pan 2010).
Extracellular signal-regulated kinase (Erk) MAPK
signaling: mitogen regulation of cell proliferation
and cell cycle progression
The ERK1/2 MAPK pathway regulates both growth in
cell size and cell cycle progression. It is activated in
Figure 2. Intracellular signaling pathways regulating growth. PI3K/TOR, Hippo, and MAPK pathways regulate growth by modulating
protein translation, cell cycle progression, and apoptosis. Schematic of pathways showing key components. Genes highlighted in red
are mutated in human genetic syndromes that manifest growth deficiency or overgrowth. (A) Growth hormone acts systemically
through its regulation of IGF-1, which activates phosphotidyl-inosine-3 kinase (PI3K) by binding the IGF-1 receptor (IGF-1R).
Subsequent activation of downstream kinases results in increased protein translation and ribosome biosynthesis, leading to cellular
growth. The pathway is inhibited by the phosphatase PTEN and integrates multiple other signals, such as nutrient/energy levels,
through the master kinase target of rapamycin (TOR). TOR activates the ribosomal S6 kinase and facilitates eIF4E activity to promote
translation and transcription initiation. (B) The Hippo pathway restricts growth to control organ size and prevent tissue overgrowth and
tumorigenesis. The pathway is currently best defined in Drosophila, where the cell polarity protein Crumbs (Crb) and the
protocadherins Fat and Dachsous (Ds) activate Hippo kinase, which in turn activates Warts kinase. The signaling cascade negatively
regulates the transcriptional coactivator Yorkie (Yki) by retaining Yki in the cytoplasm. This restricts cell proliferation and promotes
cell death, as Yki promotes G1 progression over G0 cell cycle exit through transcriptional up-regulation of Cyclin E (CycE) and the E2F
transcription factor. Yki also has an anti-apoptotic effect by inducing inhibitor of apoptosis protein (IAP). The core pathway is
conserved in mammals: Mst1/2 (Hippo), Lats (Warts), and Yap (Yki). Homologs to Fat and Ds or the target gene bantam have not yet
been identified in mammals. (C) The MAPK (ERK) signaling cascade transduces mitogen signals, driving cellular proliferation by
promoting G1-to-S-phase progression (Meloche and Pouysse´gur 2007). Downstream, ERK kinase activates the proproliferative
transcription factors Myc and E2F as well as decreases levels of the cyclin-dependent kinase inhibitors p21 and p27. Rather than
being entirely discrete signaling pathways, these three signaling pathways (A–C) overlap; for instance, Akt inhibits Hippo activity,
while ERK phosphorylates, and thus activates, TOR.
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response to virtually all mitogenic factors in diverse cell
types (Meloche and Pouyssegur 2007). Mitogen binding
to cell surface receptors activates an intracellular cas-
cade of kinases that in turn activate the central serine/
threonine kinases ERK1/2 in this pathway, which then
phosphorylate diverse protein substrates (Lewis et al.
1998; Pearson et al. 2001; Yoon and Seger 2006). During
the cell cycle, sustained ERK1/2 activity is necessary for
the progression from G1 into S phase (Meloche and
Pouyssegur 2007). Signaling induces positive regulators
of the cell cycle and inhibits the expression of anti-
proliferative genes. D-type cyclins are induced, promot-
ing G1/S progression. Expression of Cdk inhibitors p21
and p27 is also inhibited, along with maintenance of
transcriptional repression of a variety of anti-proliferative
genes (Yamamoto et al. 2006; Meloche and Pouyssegur
2007). The ERK1/2 pathway also stimulates global pro-
tein synthesis and hence cellular growth through stimu-
lation of rapamycin (mTOR) signaling (Carriere et al.
2008; Mendoza et al. 2011).
Morphogens: controlling growth by regulation of cell
proliferation and differentiation
In Drosophila wing development, increasing or decreas-
ing signaling of the morphogens Wnt (Wingless) or TGF-b
(Decaplentaplegic) alters wing size to a much greater
extent than that resulting from manipulation of the cell
cycle or basal growth control. This demonstrates the
strength of morphogens as growth-promoting agents
(Leevers and McNeill 2005; Crickmore and Mann 2008),
which is the consequence of interlinks between growth
and pattern generation signaling pathways. For instance,
Wnt, TGF-b, Sonic Hedgehog (Shh), and Notch all impact
on Hippo pathway activity (Alarcon et al. 2009; Varelas
et al. 2010; Zhao et al. 2010; Heallen et al. 2011).
Additionally, morphogens influence cell number through
cellular differentiation that frequently results in cell cycle
exit. Morphogens may also directly influence cell number
through their action on stem cells, regulating their pro-
liferation and differentiation. The TGF-b superfamily has
a key role in stem cell fate commitment (Kitisin et al.
2007), and Wnt, FGF, Notch, and Hh are also implicated
in the maintenance of tissue homeostasis by regulation of
stem cell renewal rates, as well as in proliferation or
differentiation of progenitors (Katoh 2007).
Despite this extensive knowledge of growth-regulating
pathways in animals, how organism size is determined
remains substantially unknown. Therefore, the study of
relevant human disorders may contribute additional in-
sights. The combination of significant genetic diversity
and detailed phenotypic information in humans make us
an ideal organism for identification of such physiologi-
cally relevant genes (Brenner 2003).
Primordial dwarfism
Primordial dwarfism is a group of single-gene disorders in
which growth is profoundly restricted from very early in
development and continues to be impaired postnatally.
Individuals are of ‘‘miniature construction with approx-
imately normal anthropometric proportions’’ (McKusick
1955). In essence, this is a phenotype of extreme global
growth failure (Fig. 3A), with final adult height often
reduced to as little as 1 m (Rauch et al. 2008). Neither
intensive nutritional nor growth hormone intervention
influence growth outcome (Rauch 2011), and this group of
disorders perhaps can be best thought of as a ‘‘hypocellular’’
form of dwarfism.
In line with other body parts, most individuals with
primordial dwarfism also have a reduction in head size
in proportion to, or smaller than, their body size. This
microcephaly distinguishes this group from other forms
of dwarfism (Fig. 3C). Reduction in head size is the con-
sequence of reduced brain size (cerebral cortical volume)
that most likely reflects impaired cellular proliferation
during early fetal life, a period known to be critical in
determining mammalian brain size (Wood et al. 1967;
Friede 1989). The reduction in brain size is similar to
that seen in primary microcephaly, a disorder in which
brain growth is specifically impaired (Woods et al. 2005).
In both phenotypes, brain size is reduced to approximately
a third of normal volume, a size comparable with early
humans (Ponting and Jackson 2005). Primordial dwarfism
has sometimes been used to describe patients with normal
head size (e.g., Russell Silver syndrome); however, such
usage is varied and this category is not considered further
in this review. Formally, therefore, the conditions that we
are discussing in this review are ‘‘microcephalic primordial
dwarfism.’’
Microcephalic primordial dwarfism encompasses sev-
eral distinct disease entities, including Seckel syndrome
(Seckel 1960; Majewski and Goecke 1982), microcephalic
osteodysplastic primordial dwarfism (MOPD) types I
and II (Majewski et al. 1982a,b; Hall et al. 2004), and
Meier-Gorlin syndrome (MGS) (Gorlin et al. 1975; Bongers
et al. 2001). All are inherited as autosomal recessive traits.
Figure 3. Primordial dwarfism is a disorder of extreme global
growth failure. Diagram illustrating the proportionate scaling of
body structures in primordial dwarfism (A), relative to those of
an adult of average stature (B). (C) Reduced head size distin-
guishes primordial dwarfism from other forms of dwarfism (e.g.,
achondroplasia). Bar, 25 cm.
Klingseisen and Jackson
2014 GENES & DEVELOPMENT
Helmut Seckel described a group of patients in his 1960
monograph (Seckel 1960) with ‘‘nanocephalic dwarfism’’
that became known as Seckel syndrome. In this sense,
Seckel syndrome is a generic term for microcephalic
primordial dwarfism. However, there is substantial vari-
ation in usage of this diagnostic term (Al-Dosari et al.
2010; Kalay et al. 2011), and it has also been used
specifically to describe a group of patients with more
severe learning disability and a head size disproportion-
ately smaller than their bodies (Goodship et al. 2000; Hall
et al. 2004; Kalay et al. 2011). Facial features of a receding
forehead, prominent nose, and small chin are said to be
present (Majewski and Goecke 1982).
In contrast, MOPD II is a well-defined and recognizable
form of microcephalic dwarfism (Majewski et al. 1982a;
Hall et al. 2004; Rauch 2011). There are characteristic
skeletal features as well as distinctive facial features and
small loose secondary dentition. Despite severemicroceph-
aly (proportionate to body size), there is well-preserved
intellect. However, there is a substantial risk of neuro-
vascular complications (Bober et al. 2010) from both brain
aneurysms and arterial narrowings that result in multiple
fragile collateral blood vessels (moyamoya). Most indi-
viduals also develop significant insulin resistance dur-
ing childhood, leading to skin pigmentation (acanthosis
nigricans) and type II diabetes mellitus (Huang-Doran et al.
2011).
The clinically most severe form of osteodysplastic
primordial dwarfism, Taybi-Linder syndrome (also known
as MOPD type I or III), has short bowed long bones and
profound growth retardation and is lethal within the first 3
yr. It is particularly distinguished by severe brain malfor-
mations of the cerebral cortex (pachygyria/aygyria), dry
skin, and sparse hair (Sigaudy et al. 1998).
MGS (ear, patella, and short stature syndrome) is a
further distinct primordial dwarfism syndrome defined
by absent/hypoplastic patellae and markedly small ears
(Gorlin et al. 1975; Bongers et al. 2001). Many, but not all,
cases have normal intellect with (proportionate) micro-
cephaly, and although some have growth failure as severe
as MOPD II, growth failure is variable and can be mild
(Bicknell et al. 2011a).
Finally, there are other disorders that can be associ-
ated with such substantial growth failure and micro-
cephaly that they overlap with the microcephalic pri-
mordial dwarfism group. However, these have additional
features that distinguish them, such as distinctive mal-
formations (e.g., Cornelia de Lange syndrome) (Liu and
Krantz 2009) or those with immunodeficiency and/or
significant cancer predisposition (e.g., Bloom’s syn-
drome) (Hanada and Hickson 2007). They are therefore
generally categorized as distinct disease entities. Similarly,
there are a substantial number of primordial dwarfism
cases that cannot be precisely classified within current
diagnostic schemes.
Genes mutated in primordial dwarfism
To date, 10 genes have been associated withmicrocephalic
primordial dwarfism, seven of which have been published
in the last 6 mo (Table 1). Many of these genes have been
found to encode proteins that overlap in function, associ-
ating the phenotype with specific biological processes.
Defective ataxia-telangiectasia and Rad3-related
(ATR)-dependent damage signaling
in Seckel syndrome
The first gene to be identified was ATR, a key phospho-
tidyl-inosine-3 kinase (PI3K)-like kinase that signals
DNA damage (O’Driscoll et al. 2003). ATR is a master
regulator of a DNA damage response signaling cascade
that responds to RPA-coated ssDNA substrates generated
by DNA damage, including those produced at stalled
replication forks (for review, see Cimprich and Cortez
2008). It has many similarities to ATM, another PI3K-like
kinase that activates a similar, overlapping signaling cas-
cade in response to dsDNA breaks (Shiloh 2001). However,
unlike ATM, ATR is an essential gene, due to its role in
either regulating orderly cell cycle progression from S
phase to mitosis or constitutively stabilizing stalled repli-
cation forks that arise physiologically in unperturbed cells
(Cimprich and Cortez 2008).
A synonymous homozygous mutation affecting splic-
ing was identified in individuals with Seckel syndrome
from two related families (O’Driscoll et al. 2003). This
translationally silent mutation led to marked depletion
of functional ATR protein through disruption of normal
splicing of the gene. Patient cells were found to have a
deficient response to ATR-specific damage induction,
including defective phosphorlyation of H2AX, a key his-
tonemarker of sites of DNA damage and an early event in
ATR signal activation. No further mutations have yet
been reported in ATR; however, other Seckel syndrome
patients have been subsequently found to have defects in
ATR signaling (Alderton et al. 2004). Almost all of these
cell lines were defective in downstream elements of the
ATR signaling pathway, with normal levels of H2AX
phosphorylation occurring, suggesting that mutations
encoding other components of this cellular pathway could
also cause Seckel syndrome.
Centrosomes and primordial dwarfism
The next gene to be identified was Pericentrin (PCNT),
simultaneously reported by two groups (Griffith et al. 2008;
Rauch et al. 2008). It encodes a core centrosomal protein
that, as a major constituent of the pericentriolar material,
facilitates nucleation of the mitotic spindle (Doxsey et al.
1994). Multiple biallelic truncating mutations were iden-
tified distributed throughout the gene, which would be
expected to completely abrogate protein function. This was
surprising, as it had been thought to be an essential protein,
given it is required for normal mitosis and primary cilia
formation in cell culture (Doxsey et al. 1994; Jurczyk et al.
2004). PCNT patient cells exhibit abnormal mitosis, with
impaired mitotic spindle formation and monopolar spin-
dles evident (Rauch et al. 2008), presumably as the conse-
quence of impaired recruitment of g-tubulin during cen-
trosome maturation (Griffith et al. 2008). Consequently,
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cellular proliferation is probably impaired in PCNT patient
cells, and a reduction in cell number could then account for
the substantial growth failure seen.
However, in addition to its structural role, PCNT is
also a scaffold for recruiting proteins such as protein
kinase A and CII to the centrosome (Diviani et al. 2000;
Chen et al. 2004). Given previous work suggesting ATR
signaling defects in Seckel syndrome (Alderton et al.
2004), DNA damage response signaling was assessed in
PCNT patients. Surprisingly, PCNT patient cell lines
were also defective in ATR-dependent DNA damage
response signaling, linking this pathway to the centro-
some (Fig. 4A; Griffith et al. 2008). Furthermore, although
cells exhibited a defective G2/M checkpoint in response
to activation of ATR signaling by UV-C treatment, ATM-
dependent signaling remained intact, as cells arrested
normally in response to ionizing radiation. PCNT has
subsequently been shown to act in ATR-dependent dam-
age, signaling G2/M arrest by localizing the effector
kinase Chk1 to the centrosome (Tibelius et al. 2009).
Centrosomal Chk1 inhibits G2/M transition through
inhibition of Cdc25, which in turn inhibits the Cyclin
B/Cdk1 kinase (Kramer et al. 2004). However, it is worth
noting that a recent study potentially challenges this
model, given its reassignment of the centrosomal immu-
nofluorescence signal of the Chk1 monoclonal antibody
(DCS-310) to Ccdc151 (Matsuyama et al. 2011). It also
suggests that it is nuclear rather than centrosomal Chk1
that regulates mitotic entry. Hence, precisely how Peri-
centrin acts in ATR signaling is yet be finalized.
MCPH1, a protein mutated in primary microcephaly,
a disorder of reduced brain size, acts as a downstream
component of the ATR signaling pathway (Alderton et al.
2006); therefore, mutations in ATR, PCNT, and MCPH1
could all determine size through their regulation of
mitotic entry and/or response to DNA damage. This also
suggests a functional link between primary microcephaly
and microcephalic dwarfism, and there is increasing evi-
dence of overlap between these conditions (Al-Dosari et al.
2010; Guernsey et al. 2010; Kalay et al. 2011). Several
other genes encoding centrosomal proteins cause primary
microcephaly (Thornton and Woods 2009; Nicholas et al.
2010). Intriguingly,CEP152, encoding a centrosomal gene
required for centriolar duplication (Blachon et al. 2008),
has been identified as both a primary microcephaly and
Seckel syndrome gene in the last year (Guernsey et al.
2010; Kalay et al. 2011). CEP152 also appears to have an
unexpected role in maintaining genome integrity and
may also interact with ATR through its interaction with
CINP, a protein that in turn interacts with the ATR-
interacting protein ATRIP (Fig. 4A). Likewise, mutation
of CPAP (also known as CENPJ) causes both primary
Table 1. Microcephalic primordial dwarfism genes
Gene Condition
Gene
function
Mutation
type(s)
Distinguishing
features
ATR Seckel Master kinase of a
DNA damage
response signaling
pathway
Splicing—partial
loss of function
Moderate learning disability, more
marked microcephaly than height
reduction
PCNT MOPD IIa Centrosome: major
component of
pericentriolar
material; scaffold for
signaling molecules
(ATR signaling)
Null, truncating
mutations
Skeletal; normal intellect, insulin
resistance; neurovascular
complications; small loose teeth
CPAP (CENPJ) Seckelb Centriole biogenesis Splice site mutation Proportionate microcephaly and
height reduction; mild learning
disability
CEP152 Seckelb Centriole biogenesis,
genome stability
Splice site/missense
mutations; partial
loss of function
Moderate learning disability, more
marked microcephaly
ORC1 Meier-Gorlin Components of
preRC that licenses
replication origins
Partial loss of
function
Reduced external ear size,
absence/hypoplasia of the patella;
growth more variably affected;
normal intellect
ORC4
ORC6
CDT1
CDC6
U4atac MOPD I Component of the
minor spliceosome
Hypomorphic
mutations
Skeletal; brain malformations;
lethal early childhood
IGF1 IGF1
deficiency
Endocrine/paracrine
growth hormone
Null/partial loss of
function (also one
dominant mutation
described)
Sensorineural hearing loss
aOne of the initial reports found mutations in patients with a diagnosis of Seckel syndrome, while the other identified multiple
mutations in MOPD II patients. Subsequently, it has been established that patients with PCNT mutations are best described as having
MOPD II (Griffith et al. 2008; Rauch et al. 2008; Willems et al. 2009).
bAlso associated with mutations in primary microcephaly. CPAP is also known as CENPJ.
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microcephaly and Seckel syndrome (Bond et al. 2005;
Al-Dosari et al. 2010). CPAP is the mammalian ortholog
of Sas4 (Carvalho-Santos et al. 2010), which is another
key element in centriole biogenesis; however, no role in
DNA damage response has been described as yet for this
protein.
The prereplicative complex (preRC) and MGS
Recently, a functionally distinct group of genes has been
identified. Mutations have been found in ORC1 (origin
recognition complex 1),ORC4,ORC6, CDT1, and CDC6
in patients with MGS (Bicknell et al. 2011a,b; Guernsey
et al. 2011). All five genes are components of the preRC
(Fig. 4B), which assembles on genomic DNA at origins of
replication (Mendez and Stillman 2003). The complex is
formed by the loading of the ORC (comprising ORC1–6
proteins) onto chromatin duringM and early G1 phases of
the cell cycle. Further proteins, including CDC6 and
CDT1, are recruited, and the complex then loads the
multimeric MCM helicase to complete licensing of the
origin. The partial loss-of-function mutations in MGS
patients probably impairs this process, leading to reduced
MCM helicase loading and consequently less replication
origins being licensed.
ORC1 patient cells have reduced levels of chromatin-
bound MCM protein and their ability to license origins is
impaired; however, they proliferate well in cell culture
(Bicknell et al. 2011b). This may be explained by the
substantial excess of origins that are licensed, leading to
many remaining dormant origins during unperturbed
genome replication (Woodward et al. 2006). Subtle defects
in cell cycle progression were still evident in the patient
cells, with delayed G1/S transition and S-phase progres-
sion. The former is probably the consequence of activa-
tion of a ‘‘licensing checkpoint’’ that acts in primary cells
to delay S-phase entry until a critical level of licensed
origins has been reached (Ge and Blow 2009; Nevis et al.
2009), while the latter may be the consequence of reduced
origin utilization. Notably, in Orc1-depleted zebrafish
embryos (Bicknell et al. 2011b) or Saccharomyces cerevi-
siae cells carrying the Orc4 Y232C mutation (Guernsey
et al. 2011), growth was substantially reduced. Cell
division is much more rapid in both of these situations
than for mammalian cells in culture, suggesting that
preRC function might become limiting during very rapid
cell cycles. In mammalian development, rapid cellular
proliferation (for instance, neural progenitors during early
neurogenesis) is associated with substantial shortening of
G1 (Takahashi et al. 1995). This would reduce the time
available for origin licensing, and hence impaired preRC
function could then become rate-limiting, slowing cellu-
lar proliferation. This would consequently reduce total
cell number and, as a result, organism size.
An alternative is that mutations act in a process in-
dependent of replication licensing, since individual ORC
genes are also involved in diverse cellular processes,
including heterochromatin formation, gene silencing,
Figure 4. Cellular pathways implicated in primordial
dwarfism. (A) ATR DNA damage response signaling.
The ATR kinase is activated in response to ssDNA
generated by DNA damage. It phosphorylates down-
stream targets, including the effector kinase Chk1, to
coordinate cell cycle arrest, repair the damage, and/or
induce apoptosis. Phosphorylation of Chk1 is required
for its accumulation at the centrosome (Niida et al.
2007), where it inhibits Cdc25B phosphatase, prevent-
ing Cdk1/Cyclin B activation and the transition from
G2 to mitosis (Kramer et al. 2004). MCPH1 and PCNT
are required for Chk1 localization at the centrosome,
and therefore mutations in these genes also impair
ATR-induced G2/M checkpoint signaling. Another pri-
mordial dwarfism gene, CEP152, interacts with ATR
through binding of CINP, which in turn interacts with
ATRIP. Genes mutated in primordial dwarfism/primary
microcephaly are highlighted in white text. (B) Licens-
ing of replication origins. During G1, the six-subunit
ORC assembles at origins of replication. Once the ORC
complex is formed, additional factors such as CDC6
and CDT1 are recruited, permitting reiterative loading
of the MCM helicase complex (MCM2–7). After G1/
S-phase transition, DNA replication is then initiated by
the binding of additional factors and the MCM helicase
unwinding DNA at replication forks. (C) mRNA splic-
ing. Splicing of a subpopulation of mRNAs that contain
U12-type introns is dependent on the minor spliceosome. The small nuclear ncRNA U4atac is one component of this alternative
spliceosome, and mutations in U4atac impair splicing of such introns to a variable degree. U12-dependent introns are found in many
genes, including those involved in DNA replication and growth, such as ORC3, MAPKs 1–4, PTEN, and PI3K adaptor protein 1. The
exon junction complex (EJC) protein Magoh has also recently been found to be required for splicing of specific genes, including mapk in
Drosophila and Lis1 in mice, where it causes microcephaly and growth retardation.
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and mitosis (Sasaki and Gilbert 2007). Such noncanonical
functions could also explain the specific developmental
abnormalities seen in MGS patients (absent patella,
marked reduction in ear size, and additional malforma-
tions, including lower limb deformities, congenital lobar
emphysema, and neuronal migration defects). Further-
more, such an association between chromatin-bound
complexes involved in essential cellular functions and
development is not unprecedented. Notably, in Cornelia
de Lange syndrome, mutations in the cohesin complex
also cause severe growth retardation, although with very
different developmental consequences (Liu and Krantz
2009). However, the identification of mutations in so
many ORC subunits, along with the involvement of
CDT1 and CDC6, strongly suggests that licensing lies
at the heart of pathogenesis in MGS.
Splicing machinery and MOPD I
Mutation of a minor spliceosome component, the U4atac
snRNA, has been recently identified for MOPD I (Edery
et al. 2011; He et al. 2011). This lethal condition exhibits
profound growth retardation as well as skeletal and brain
malformations. The mutations identified generally target
a functionally important hairpin loop of this RNA,
impairing its role in splicing a small subset of introns,
named ‘‘U12 introns’’ (Fig. 4C; Tarn and Steitz 1996).
Such introns are only present in ;700 human genes
(Sheth et al. 2006) that encode proteins with a diverse
range of functions, including those involved in DNA
replication and repair, transcription, RNA processing,
and translation (Will and Luhrmann 2005). Expression
of some U12-type intron-containing genes appears to be
more markedly impaired than others by U4atac snRNA
mutations in both humans and Drosophila (Pessa et al.
2010; Edery et al. 2011; He et al. 2011), and it is suggested
that perturbation of specific gene transcripts could ex-
plain the phenotype.
IGF1 deficiency phenocopies primordial dwarfism
Growth hormone deficiency and other GH axis defects
cause a very marked reduction in final adult height.
However, growth failure is generally postnatal and brain
size is spared. In contrast, loss of IGF1 function specifi-
cally causes a phenotype that is indistinguishable from
primordial dwarfism, with microcephaly and growth fail-
ure similar to that seen in MOPD II (Netchine et al.
2011). In contrast to IGF1, GH is not active prenatally,
most likely explaining the difference in phenotypes.
Notably, most patients with mutations in IGF1 have
sensorineural hearing loss and learning difficulties, per-
haps suggesting a specific neurodevelopmental require-
ment for IGF1.
Overlapping mechanisms of growth failure
in primordial dwarfism?
The identified primordial dwarfism genes appear to be
involved in overlapping processes regulating cellular pro-
liferation. They do not fall neatly into one cellular process,
yet there are interesting functional overlaps (Fig. 5).
A cellular pathway in which ATR signaling intersects
with centrosomal proteins appears to be one major
emerging theme in microcephalic primordial dwarfism.
So, how may mutations act on these processes to cause
dwarfism? First, impaired DNA damage response signal-
ing could alter the cellular threshold for cell death
resulting fromDNAdamage, increasing levels of apoptosis
during development. Programmed cell death has a sub-
stantial effect in determining organ size during develop-
ment (Kuida et al. 1998; Roth et al. 2000). Growth failure
and microcephaly in humans/mice with Ligase IV (LIG4)
mutations (Nijnik et al. 2007; Chistiakov et al. 2009) may
be the consequence of DNA damage response activation,
resulting in substantial apoptosis during development
(Frank et al. 2000; Lee et al. 2000). However, in Ligase
IV mice, an increase in damage repair also decreases the
proliferative potential of progenitors, leading to exhaus-
tion of stem cell pools (Nijnik et al. 2007). Second,
mutations may alter the dynamics of mitosis. This is
most evident for the centrosomal proteins such as PCNT
and CEP152, where mutations lead to impaired mitotic
spindle formation (Rauch et al. 2008; Kalay et al. 2011),
which could delay mitotic progression and increase the
Figure 5. Primordial dwarfism genes act in processes
regulating cell cycle progression. Schematic of nuclear and
centrosome cycles. Centrosome and genomic DNA dupli-
cation are coordinately regulated, with both occurring only
once per cell cycle. Mutations in preRC complex proteins
impair G1/S transition and S-phase progression. They may
also increase replication stress through fewer licensed
origins being present. ATR also regulates S-phase progres-
sion, as ATR-Seckel mice have increased replication stress
during embryogenesis. ATR is then required during G2/M
transition, signaling via Chk1 at the centrosome, with
localization of Chk1 dependent on MCPH1 and PCNT.
PCNT and CEP152 are required for nucleation of the
mitotic spindle. Additionally, CEP152 and CPAP (CENPJ),
as components of the centriole biogenesis machinery, are
essential for centriole duplication, which may also impact
on mitotic centrosome integrity later in the cell cycle.
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proportion of nonviable cell divisions. Third, stem cells
may be specifically affected by perturbed centrosomal
function. Stem cells undergo asymmetric cell division to
generate committed progeny while maintaining their
‘‘stem cell identity,’’ with centrosomes playing an impor-
tant role in such divisions (Knoblich 2010). Notably, ATR
and Chk1 have also been found to play a role in asym-
metric cell division in the C. elegans embryo, where they
act to delay subsequent cell cycle progression specifically
in one daughter cell relative to the other (Brauchle et al.
2003). This delay may well have consequences for sub-
sequent developmental fate determination (Budirahardja
and Gonczy 2009). Last, the analysis of an ATR mouse
model that recapitulates the Seckel syndrome suggests
that increased replication stress may be responsible for
the phenotype (Murga et al. 2009). Increased replication
stress was observed specifically during embryogenesis,
associated with raised levels of apoptosis.
ATR has a physiological role in minimizing the dele-
terious consequences of replication stress resulting from
stalled replication forks by reshaping replication origin
utilization, directing replication toward active factories
where replication forks are inhibited, while inhibiting
origin initiation elsewhere (Ge and Blow 2010). Replica-
tion stress may therefore also be relevant to etiology of
MGS; notably, cellular depletion of the MCM helicase
complex leads to increased sensitivity to replication stress
(Ge et al. 2007). Mutations in MCM subunits can also
impair growth inmice (Chuang et al. 2010). However, such
mice also have increased genome instability and cancer
predisposition (Shima et al. 2007; Chuang et al. 2010),
a feature not evident in MGS patients, suggesting that
mutations in MGS genes could be functionally distinct.
Overall, themost plausible unifying hypothesis is that by
reducing the efficiency of cell cycle progression, primordial
dwarfism genes act to reduce the total cell number gener-
ated during development, leading to reduced tissue and
organism size. U4atac snRNA mutations do not immedi-
ately fit into such amodel. However, the effect on transcript
splicing is selective (Pessa et al. 2010; Edery et al. 2011; He
et al. 2011), and it is quite possible that specific impairment
of one of the U12-type intron-containing genes involved in
cell cycle control (Sheth et al. 2006) causes the growth
failure. Intriguingly, Orc3 is one such gene (Alioto 2007).
ENU-induced mutation in a component of another
mRNA transcript-binding complex also influences splic-
ing, causingmicrocephaly and growth retardation inmice
(Silver et al. 2010). MAGOH is a component of the exon
junction complex that binds upstream of spliced exons,
and, consequently, selective loss of Lis1 (a neuronal pro-
liferation/migration gene) transcripts was seen in mice.
Likewise, in Drosophila, mutation of magoh resulted in
reduced MAPK transcript levels (Roignant and Treisman
2010; Silver et al. 2010).
Are primordial dwarfism genes regulators
of physiological growth?
Growth is a highly complex process with multiple levels
of developmental regulation, exemplified by the 180
height loci identified by human genome-wide association
studies (GWAS) studies (Lango Allen et al. 2010). With
such complexity, growth failure may therefore often
result from secondary consequences rather than primary
effects on growth regulatory pathways. Although primor-
dial dwarfism genes are clearly able to alter body size, it
thus does not necessarily follow that they are used as
physiological regulators of growth. Growth failure could
simply be the result of reduced cellular proliferation.
However, there are some lines of evidence that could
suggest physiological roles for some primordial dwarfism
genes. First, the phenotype is consistent with a direct
effect on growth, with generally proportionate scaling in
the body’s structures without other substantial develop-
mental or health problems. Second, phenotype-driven
developmental screens for growth have been very suc-
cessful in identifying important signaling pathways in
model organisms (Stocker and Hafen 2000), and there is
no reason why human phenotypes should be less in-
formative. Indeed, a significant number of single-gene
human disorders that manifest growth failure or over-
growth have mutations in MAPK signaling pathways or
IGF1/TOR signaling pathways (genes in red in Fig. 3).
Third, the role of primordial dwarfism genes in cellular
proliferation provides functional plausibility, particularly
given that this is an ultimate target of growth signaling
pathways. Last, several of these genes are regulated by
known effector proteins of these growth pathways. For
instance, E2F transcription factors (downstream from
IGF1 and Hippo signaling) regulate ORC1, CDC6 and
MCM gene transcription (Ohtani et al. 1996, 1998, 1999;
Asano and Wharton 1999), while Myc has been reported
to have a nontranscriptional regulative role, directly
binding the preRC complex and modulating origin activ-
ity (Dominguez-Sola et al. 2007).
Regulating body size through cell proliferation is a con-
ceptually simple mechanism for scaling organism size
proportionately. It is striking that most genes identified
to date have not been identified as components of core
intracellular growth signal transduction pathways. Per-
haps this is the result of such signal transduction proteins
integrating multiple signals, as well as the interdepen-
dent relationships between morphogenetic and growth
signaling networks. Thus, disrupting such genesmay lead,
respectively, to disproportionate local effects on growth or
deleterious developmental consequences. For instance,
disruption of the Hippo pathway will most likely result
in regional rather than global size changes, as conditional
ablation of the murine Mst (Hippo) gene using the
tamoxifen-inducible CAGGCre-ER line has dramatic
effects on the growth of the liver and stomach, but not
on the kidney or limb (Song et al. 2010). Likewise, human
mutations in MAPK pathway components results in
specific developmental defects (e.g., neurocognitive, pig-
mentary, and cardiac) as the consequence of the pathway’s
role in diverse cellular processes (Denayer et al. 2008).
Uniquely among developmental signaling pathway
genes, mutations in IGF-1 mutations result in the pri-
mordial dwarfism phenotype, confirming that at least for
this gene, the phenotype is associated with physiological
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growth regulation. In other organisms, IGF1 is also an
important determinant of body size. For instance, a regu-
latory polymorphism of IGF-1 is themajor determinant of
body size in dogs (Sutter et al. 2007), determining the
difference between Chihuahuas and Great Danes. Similar
phenotypes could suggest a functional link between IGF-1
and other microcephalic primordial dwarfism genes.
However, a shared function is not immediately evident,
given that IGF1 acts on cell mass to determine growth
while the other genes are involved in cell proliferation.
This may most easily be clarified by determining the
consequence for cell size and number of such primordial
dwarfism mutations.
Height in humans is a highly heritable trait for which
90% of genetic variability still remains unaccounted
(Lango Allen et al. 2010). This is despite human GWAS of
sequence variants influencing height in studies totaling
184,000 individuals. Mutations in primordial dwarfism
genes dramatically affect body size, often proportionately
scaling body structures, although, surprisingly, these genes
have not been detected in GWAS studies. However, mod-
erate effect variants in the coding or regulatory regions of
these genes could well be an important source of physio-
logical regulation of height/body size, accounting for some
of the ‘‘dark matter’’ of unidentified genetic variability.
In summary, it is not yet clear whether the primordial
dwarfism genes will generally have a role in physiological
growth regulation. It could well be that mutations in
these genes simply impair cell division, resulting in
decreased organism size, and have no physiological role.
We may therefore need to await the identification of
further primordial dwarfism genes, as well as investigate
other human phenotypes, to find novel physiological
regulators. In particular, study of human overgrowth
syndromes may be informative, analogous to the utility
that longevity mutants have had in aging research
(Honjoh and Nishida 2011). Such overgrowth syndromes
already implicate IGF1/TOR signaling, cell cycle regula-
tors, and chromatin-binding proteins in human growth
determination (Rahman 2005; Kant et al. 2007; Verge and
Mowat 2010).
Conclusions
As a whole, the primordial dwarfism genes are involved
in cell cycle progression, with organism size most likely
reduced in these conditions through reduced cell number.
Pathways and functional relationships exist between
many of these genes, but they do not fall neatly into
one cellular pathway. However, identification of these
genes has already provided substantial new insights, such
as linking core centrosomal proteins with DNA damage
response (Griffith et al. 2008) as well as demonstrating
that defects in fundamental replication proteins lead to
reduced growth and specific developmental anomalies
(Bicknell et al. 2011a,b; Guernsey et al. 2011).
Several interesting questions are raised by the identifi-
cation of primordial dwarfism genes. First, do these genes
act through a general slowing of proliferation in all cells
or by specific targeting of rapidly proliferating cells or
stem cell division? It is intriguing that the organism does
not simply grow for longer to catch up, given established
mechanisms that compensate cell size with cell number
to maintain a fixed organism mass (Conlon and Raff
1999). Second, do they help to explain evolutionary
differences in size between species and within species?
Third, in metazoans, growth regulation of cell prolifera-
tion appears to be mostly targeted at G1/S progression,
but given the known functions of primordial dwarfism
genes, is centrosome function and/or the G2/M check-
point involved in growth regulation? Finally, how could
direct effects on cell cycle progression result in propor-
tionate scaling of organism size? Transplantation exper-
iments suggest that organs ‘‘know’’ their size, but how
this is set in the context of overall organism size is not
established. Organ size could be predetermined at an
early stage by progenitor cell number, and this appears to
be the case for some organs, but not others (Stanger et al.
2007). Alternatively, systemic (endocrine) signals might
respond to adjust organ size in response to the altered cell
number and total body mass.
We are at an early stage in understanding the role of
primordial dwarfism genes in growth, and further de-
velopmental and cellular studies will no doubt provide
useful insights. Additionally, many genes remain to be
identified for microcephalic primordial dwarfism and
could well provide additional surprises. It is hoped that
further study of these disorders will advance understand-
ing of the basic mechanisms regulating growth, relevant to
human health, and understanding of the evolution of body
size. The linkage of such fundamental genes to disease also
prompts re-evaluation of assumed functions of these genes
both at the cellular level and developmentally.
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